Ionis Pharmaceuticals IONS Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's total liabilities & equity?
- Ionis Pharmaceuticals (IONS) reported total liabilities & equity of $3.45B in Q1 2026.
- How has Ionis Pharmaceuticals's total liabilities & equity changed year-over-year?
- Ionis Pharmaceuticals's total liabilities & equity increased by 22.6% year-over-year, from $2.81B to $3.45B.
- What is the long-term trend for Ionis Pharmaceuticals's total liabilities & equity?
- Over 5 years (2020 to 2025), Ionis Pharmaceuticals's total liabilities & equity has grown at a 8.1% compound annual growth rate (CAGR), from $2.39B to $3.52B.
- What does total liabilities & equity mean?
- The total size of the company's balance sheet, representing all sources of funding.
- How do you interpret total liabilities & equity?
- Growth in this figure typically tracks the expansion of the company's asset base and operational scale.
- How does total liabilities & equity compare across companies?
- Standard accounting identity used to verify balance sheet integrity across all industries.